Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)

Julie K. Bower, James S. Pankow, Mariana Lazo-Elizondo, Eric Christenson, Ron C. Hoogeveen, Christie M. Ballantyne, Marc K Halushka, Brad C. Astor, Elizabeth Selvin

Research output: Contribution to journalArticle

Abstract

Objectives: The soluble receptor for advanced glycation end products (sRAGE) has been implicated in the development of diabetes-related vascular complications, but the variability of concentrations of sRAGE in the blood is unknown. The objective of this study was to characterize within-person three-year variability of plasma levels of sRAGE. Design and methods: We measured sRAGE in plasma samples from 179 men and women in the community-based Atherosclerosis Risk in Communities (ARIC) Study at two time points, three years apart. We calculated correlation coefficients and the within-person coefficient of variation (CVw) to characterize variability in sRAGE. We compared these estimates to total cholesterol and white blood cell count (WBC) in the same participants. Results: Mean sRAGE concentrations at the two time points (mean time between measurements=2.9years) were 1096.2pg/mL and 990.2pg/mL, respectively (mean difference=-106.0pg/mL, p-valuew was 26.6%. Compared to sRAGE, Pearson's and Spearman's correlations for total cholesterol (0.76 and 0.77) and white blood cell count (0.61 and 0.72) were similar, although CVw for both was lower (8.7% for cholesterol, 15.6% for WBC). Less than 4% of participants' values changed substantially (50% or greater) over the three-year interval. Conclusions: We observed that sRAGE concentrations remained relatively stable over three years. Our findings suggest that a single measure of circulating sRAGE tracks well in a community-based population and could be a useful measure in clinical and epidemiologic studies of long-term risk.

Original languageEnglish (US)
Pages (from-to)132-134
Number of pages3
JournalClinical Biochemistry
Volume47
Issue number1-2
DOIs
StatePublished - Jan 2014

Fingerprint

Plasmas
Blood
Leukocyte Count
Cholesterol
Cells
Advanced Glycosylation End Product-Specific Receptor
Diabetes Complications
Medical problems
Time measurement
Blood Vessels
Epidemiologic Studies
Atherosclerosis
Population

Keywords

  • Advanced glycation end products
  • Biological markers
  • Reliability and validity

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). / Bower, Julie K.; Pankow, James S.; Lazo-Elizondo, Mariana; Christenson, Eric; Hoogeveen, Ron C.; Ballantyne, Christie M.; Halushka, Marc K; Astor, Brad C.; Selvin, Elizabeth.

In: Clinical Biochemistry, Vol. 47, No. 1-2, 01.2014, p. 132-134.

Research output: Contribution to journalArticle

Bower, Julie K. ; Pankow, James S. ; Lazo-Elizondo, Mariana ; Christenson, Eric ; Hoogeveen, Ron C. ; Ballantyne, Christie M. ; Halushka, Marc K ; Astor, Brad C. ; Selvin, Elizabeth. / Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). In: Clinical Biochemistry. 2014 ; Vol. 47, No. 1-2. pp. 132-134.
@article{f15e1920166948ee93e4b9246b5b26e1,
title = "Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)",
abstract = "Objectives: The soluble receptor for advanced glycation end products (sRAGE) has been implicated in the development of diabetes-related vascular complications, but the variability of concentrations of sRAGE in the blood is unknown. The objective of this study was to characterize within-person three-year variability of plasma levels of sRAGE. Design and methods: We measured sRAGE in plasma samples from 179 men and women in the community-based Atherosclerosis Risk in Communities (ARIC) Study at two time points, three years apart. We calculated correlation coefficients and the within-person coefficient of variation (CVw) to characterize variability in sRAGE. We compared these estimates to total cholesterol and white blood cell count (WBC) in the same participants. Results: Mean sRAGE concentrations at the two time points (mean time between measurements=2.9years) were 1096.2pg/mL and 990.2pg/mL, respectively (mean difference=-106.0pg/mL, p-valuew was 26.6{\%}. Compared to sRAGE, Pearson's and Spearman's correlations for total cholesterol (0.76 and 0.77) and white blood cell count (0.61 and 0.72) were similar, although CVw for both was lower (8.7{\%} for cholesterol, 15.6{\%} for WBC). Less than 4{\%} of participants' values changed substantially (50{\%} or greater) over the three-year interval. Conclusions: We observed that sRAGE concentrations remained relatively stable over three years. Our findings suggest that a single measure of circulating sRAGE tracks well in a community-based population and could be a useful measure in clinical and epidemiologic studies of long-term risk.",
keywords = "Advanced glycation end products, Biological markers, Reliability and validity",
author = "Bower, {Julie K.} and Pankow, {James S.} and Mariana Lazo-Elizondo and Eric Christenson and Hoogeveen, {Ron C.} and Ballantyne, {Christie M.} and Halushka, {Marc K} and Astor, {Brad C.} and Elizabeth Selvin",
year = "2014",
month = "1",
doi = "10.1016/j.clinbiochem.2013.11.005",
language = "English (US)",
volume = "47",
pages = "132--134",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)

AU - Bower, Julie K.

AU - Pankow, James S.

AU - Lazo-Elizondo, Mariana

AU - Christenson, Eric

AU - Hoogeveen, Ron C.

AU - Ballantyne, Christie M.

AU - Halushka, Marc K

AU - Astor, Brad C.

AU - Selvin, Elizabeth

PY - 2014/1

Y1 - 2014/1

N2 - Objectives: The soluble receptor for advanced glycation end products (sRAGE) has been implicated in the development of diabetes-related vascular complications, but the variability of concentrations of sRAGE in the blood is unknown. The objective of this study was to characterize within-person three-year variability of plasma levels of sRAGE. Design and methods: We measured sRAGE in plasma samples from 179 men and women in the community-based Atherosclerosis Risk in Communities (ARIC) Study at two time points, three years apart. We calculated correlation coefficients and the within-person coefficient of variation (CVw) to characterize variability in sRAGE. We compared these estimates to total cholesterol and white blood cell count (WBC) in the same participants. Results: Mean sRAGE concentrations at the two time points (mean time between measurements=2.9years) were 1096.2pg/mL and 990.2pg/mL, respectively (mean difference=-106.0pg/mL, p-valuew was 26.6%. Compared to sRAGE, Pearson's and Spearman's correlations for total cholesterol (0.76 and 0.77) and white blood cell count (0.61 and 0.72) were similar, although CVw for both was lower (8.7% for cholesterol, 15.6% for WBC). Less than 4% of participants' values changed substantially (50% or greater) over the three-year interval. Conclusions: We observed that sRAGE concentrations remained relatively stable over three years. Our findings suggest that a single measure of circulating sRAGE tracks well in a community-based population and could be a useful measure in clinical and epidemiologic studies of long-term risk.

AB - Objectives: The soluble receptor for advanced glycation end products (sRAGE) has been implicated in the development of diabetes-related vascular complications, but the variability of concentrations of sRAGE in the blood is unknown. The objective of this study was to characterize within-person three-year variability of plasma levels of sRAGE. Design and methods: We measured sRAGE in plasma samples from 179 men and women in the community-based Atherosclerosis Risk in Communities (ARIC) Study at two time points, three years apart. We calculated correlation coefficients and the within-person coefficient of variation (CVw) to characterize variability in sRAGE. We compared these estimates to total cholesterol and white blood cell count (WBC) in the same participants. Results: Mean sRAGE concentrations at the two time points (mean time between measurements=2.9years) were 1096.2pg/mL and 990.2pg/mL, respectively (mean difference=-106.0pg/mL, p-valuew was 26.6%. Compared to sRAGE, Pearson's and Spearman's correlations for total cholesterol (0.76 and 0.77) and white blood cell count (0.61 and 0.72) were similar, although CVw for both was lower (8.7% for cholesterol, 15.6% for WBC). Less than 4% of participants' values changed substantially (50% or greater) over the three-year interval. Conclusions: We observed that sRAGE concentrations remained relatively stable over three years. Our findings suggest that a single measure of circulating sRAGE tracks well in a community-based population and could be a useful measure in clinical and epidemiologic studies of long-term risk.

KW - Advanced glycation end products

KW - Biological markers

KW - Reliability and validity

UR - http://www.scopus.com/inward/record.url?scp=84890548356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890548356&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2013.11.005

DO - 10.1016/j.clinbiochem.2013.11.005

M3 - Article

C2 - 24246851

AN - SCOPUS:84890548356

VL - 47

SP - 132

EP - 134

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 1-2

ER -